{"id":50927,"date":"2022-11-16T11:02:08","date_gmt":"2022-11-16T10:02:08","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/the-worldwide-narcolepsy-therapeutics-industry-is-expected-to-reach-5-billion-by-2028-at-a-10-5-cagr-researchandmarkets-com\/"},"modified":"2022-11-16T11:02:08","modified_gmt":"2022-11-16T10:02:08","slug":"the-worldwide-narcolepsy-therapeutics-industry-is-expected-to-reach-5-billion-by-2028-at-a-10-5-cagr-researchandmarkets-com","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/the-worldwide-narcolepsy-therapeutics-industry-is-expected-to-reach-5-billion-by-2028-at-a-10-5-cagr-researchandmarkets-com\/","title":{"rendered":"The Worldwide Narcolepsy Therapeutics Industry is Expected to Reach $5 Billion by 2028 at a 10.5% CAGR – ResearchAndMarkets.com"},"content":{"rendered":"
\n

DUBLIN–(BUSINESS WIRE)–The “Global Narcolepsy Therapeutics Market Size, Share & Industry Trends Analysis Report By Type, By Product (Sodium Oxybate, Selective Serotonin Reuptake Inhibitor, Central Nervous System Stimulants, Tricyclic Antidepressants), By Regional Outlook and Forecast, 2022 – 2028”<\/a> report has been added to ResearchAndMarkets.com’s<\/strong> offering.\n<\/p>\n

<\/a><\/p>\n

\nThe Global Narcolepsy Therapeutics Market size is expected to reach $5 billion by 2028, rising at a market growth of 10.5% CAGR during the forecast period.\n<\/p>\n

\nChronic, incapacitating neurologic disease called narcolepsy is characterized by excessive daytime sleepiness (EDS). Modafinil, armodafinil, and stimulants are only a few of the medications used to treat narcolepsy. Others include sodium oxybate and venlafaxine, which are used to treat the symptoms of sleep paralysis and sleep-related hallucinations (e.g. sodium oxybate).\n<\/p>\n

\nIn general, drugs that boost norepinephrine or dopamine release or prevent their reuptake have wake-promoting effects and can help manage EDS, whereas drugs that block serotonin or norepinephrine reuptake have anti-cataplexy benefits. Both EDS and cataplexy are affected by the modification of either histamine H3 receptors (H3Rs) or -aminobutyric acid B (GABAB) receptors.\n<\/p>\n

\nThe most recent approved medications for EDS related to narcolepsy in the European Union and the USA are solriamfetol, a dopamine and norepinephrine reuptake inhibitor, and pitolisant, an H3R antagonist. Many new drugs are being developed and tested as potential treatments for EDS and cataplexy associated with narcolepsy (THN102), including novel Oxybate formulations of low sodium [FT218] and one-nightly [JZP-258], selective norepinephrine reuptake inhibitors (AXS-12), and modafinil and astroglial connexin inhibitors (THN102).\n<\/p>\n

\nThe mechanisms of action, pharmacokinetics, effectiveness, and safety\/tolerability of recently authorized and developing therapies for narcolepsy. A chronic, incapacitating neurologic condition of hypersomnolence called narcolepsy is thought to affect 20-67 persons per 100,000 people across the world. Narcolepsy typically begins in the second decade of life; however, a diagnosis is frequently made much later.\n<\/p>\n

\nExcessive daytime sleepiness (EDS), while not a specific symptom of narcolepsy, is a feature of the illness that must be present in all individuals to make the diagnosis. Up to 60% of patients have cataplexy, an involuntary decrease of muscle tone while awake that is generally brought on by intense emotions. Restless nights, hypnagogic and hypnopompic hallucinations that happen when the user falls asleep and wakes up, and sleep paralysis are other symptoms.\n<\/p>\n

\nMarket Growth Factors<\/strong>\n<\/p>\n

\nGrowing Healthcare Expenditures<\/strong>\n<\/p>\n

\nOne of the main factors boosting the market’s rise is the rising number and size of investments made in the healthcare sector by governments of various countries. It is anticipated that more developing nations is expected to have greater access to high-quality healthcare as a result of their quick economic development and growing healthcare costs. This is viewed as a positive indicator of expansion for the narcolepsy therapeutics industry. The need for various treatment and apparatus has surged in these nations due to the rising insomnia problems.\n<\/p>\n

\nIncreasing Prevalence Of Neurological Conditions<\/strong>\n<\/p>\n

\nNeurologists treat a wide variety of sleep problems, including narcolepsy, sleep apnea, restless legs syndrome, insomnia, and sleep apnea. Endogenous irregularities are brought on by several illnesses, which interfere with the regular sleep-wake cycle. In the upcoming years, neurological sleep-related diseases are predicted to rise as a significant section of the population ages. The National Institute of Health (NIH) estimates that 20 million Americans occasionally have sleep issues, whereas 40 million Americans suffer from neurological illnesses.\n<\/p>\n

\nMarket Restraining Factors<\/strong>\n<\/p>\n

\nHigh Cost Of Narcolepsy Diagnosis & Treatment<\/strong>\n<\/p>\n

\nOne of the main factors holding back the narcolepsy market is the high cost of narcolepsy diagnosis and treatment. Additionally, the term “sleeping problem” refers to a broad range of illnesses with serious negative effects on the health of the individual and huge societal costs. Furthermore, in 2019 the smooth operation of the narcolepsy market is disrupted by the high cost of therapy. Daily functioning is hampered by narcolepsy, which is also connected with a significant financial and medical burden – many patients are fully disabled.\n<\/p>\n

\nMarket Segments Covered in the Report:<\/strong>\n<\/p>\n

\nBy Type<\/strong>\n<\/p>\n